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INTRODUCTION
Autoimmune hepatitis (AIH) is a non-contagious
chronic inflammatory disease that results from
autoantibody-mediated hepatocyte injury. Auto-
immune hepatitis, primary biliary cirrhosis and primary
sclerosing cholangitis are together classified as
autoimmune liver disease.1
AIH is classified into different types on the basis of
the serum autoantibody profiles. The common
denominator for all the types is the presence of
hypergammaglobulinemia, precisely IgG.2 Type 1 AIH
is defined by the presence of antinuclear antibody
(ANA), anti-smooth muscle antibody (Anti-SMA), or
both and constitutes 80% of  AIH cases.2 It is also
commonly associated with other autoimmune diseases
like autoimmune thyroiditis, celiac disease and ulcerative
colitis, with about 25% having cirrhosis at presentation.2
Type 2 AIH is characterized by the presence of  anti-
liver kidney microsomal (Anti-LKM) 1 and/or anti-
LKM 3 and/or anti-liver cytosol 1 (Anti-LC1)
antibodies.2 It is commoner in children, acute severe
presentation does occur, and progression to cirrhosis
commonly follows.2
The diagnosis of AIH is usually suspected when
ongoing hepatocellular inflammation cannot be
explained on the basis of chronic viral infection, alcohol
consumption, or exposure to hepatotoxic medications
or chemicals.2 As such, it is often a diagnosis of
exclusion.
The incidence, prevalence and characteristics of AIH
vary in different geographical regions. On a general
note, it has a mean incidence of 1-2 per 100,000 and a
point prevalence of 11–17 per 100,000. 2 It is
commoner in women (especially young women) than
men with a ratio around 4:1 but it occurs in all age
groups, races and geographical areas.2–5 The exact
prevalence of the disease is not known in Nigeria as
most studies on CLD focused on viral hepatitis,
alcoholic liver disease and hepatocellular carcinoma.
Only one case report of AIH in Nigeria was found in
our literature search.6 A case of a 9-year-old girl with
co-occurring wild-type chronic hepatitis B and
antinuclear antibody-positive autoimmune hepatitis was
reported in Senegal, a West African country.7 We present
a young woman with liver cirrhosis that resulted from
autoimmune hepatitis. The rarity of  the disease, as well
as the scarcity of reported cases in Nigeria, necessitated
this effort.
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Autoimmune hepatitis (AIH) is a rare cause of chronic liver disease (CLD).
It presents with varied clinical features from acute hepatitis to CLDs like
chronic viral hepatitis and alcoholic liver disease, making it difficult to
diagnose in the absence of a high index of suspicion and adequate
laboratory support. Autoantibody-mediated hepatocyte injury is the major
feature of AIH.
We present a 44 year old woman with recurrent jaundice, ascites,
splenomegaly, coagulopathy, negative chronic viral hepatitis screening,
elevated IgG and positive anti-smooth muscle antibody. The patient
responded well to immunosuppressive therapy.
This report brings to the fore the need for physicians to maintain a high
index of suspicion and thoroughly evaluate all CLD cases of seemingly
‘unknown’ etiology for AIH in order to prevent progression to end-stage-
liver-disease, since the disease is highly amenable to immunosuppressive
therapy.
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CASE REPORT
A 44-year-old woman with a 4-week history of
jaundice was referred to our clinic for evaluation. She
was initially being evaluated for obstructive jaundice
by a Gastrointestinal Surgeon in our hospital before
the referral.
She had a history of dark color urine and pruritus
which was limited to the extremities for which she
was given cholestyramine by the referring doctor. She
no longer had pruritus at the time she presented at our
clinic despite having stopped taking cholestyramine.
There was abdominal pain but no fever or passage of
pale stool. No history of vomiting, diarrhea, or
abdominal swelling. No history of  blood transfusion,
intravenous drug abuse, surgery or multiple sexual
partners. Her hemoglobin genotype is AA. She had a
similar history of jaundice 7 months before her
presentation to us which resolved after receiving
unspecified treatment at another facility. She was not
previously diagnosed with any chronic illness.
She is the fifth of five children in a polygamous family
setting. She has five children. No family history of  a
similar illness.
On physical examination, she was cachectic, deeply
jaundiced but not pale. She had bilateral pitting pedal
edema. The liver span was 8cm by percussion. She
had moderate ascites, the blood pressure was normal
but there was tachycardia (pulse was 112 per minute).
The remainder of  the examination was normal.
An abdominal ultrasound scan at our facility showed
a normal sized liver (12.6cm) with mildly accentuated
echotexture. The intrahepatic ducts and the biliary tree
were within normal limits. The spleen was enlarged
(14.4cm) with normal echogenicity, both kidneys were
normal in shape, size and outline, and there was
moderate ascites.
Viral markers of hepatitis B and C (HBsAg, HBeAg,
Anti-HBe, Anti-HBc total, and Anti-HCV) were
negative. The results of other laboratory tests are as
depicted in Table 1.
A diagnosis of liver cirrhosis secondary to autoimmune
hepatitis was made at the end of the evaluation. She
was commenced on 60mg of Prednisolone which was
to be tapered off  to 20mg over 4 weeks. She
unilaterally stopped the Prednisolone 12 days after
commencement because she developed facial swelling.
At clinic presentation after the stoppage of
Prednisolone, jaundice had cleared. She was later placed
on Budesonide 3mg TID and Azathioprine 50mg daily.
Budesonide was discontinued after 4 weeks. She also
had oral spironolactone, furosemide and propranolol
in the course of treatment. She is currently on only
Azathioprine 50mg daily.
One year since commencement of treatment, she is
stable with no jaundice, ascites or pedal edema. She
has also gained some weight despite the loss of
previously accumulated fluid. Her weight at first
presentation was 45kg while her current weight is 49kg.
Tests Before Treatment After one year  of
treatment
ALT (0-22 IU/L) 347 IU/L 18 IU/L
AST (0-18 IU/L) 162 IU/L 13 IU/L
ALP (0-35 IU/L) - 18 IU/L
Total Bilirubin (up to 20umol/L) 272 umol/L 45 umol/L
Conjugated Bilirubin (up to 5umol/L) 250 umol/L 21 umol/L
Total Protein (58-80g/L) 101g/L 71g/L
Albumin (35-50g/L) 36g/L 45g/L
Platelet 122,000/mm3
Prothrombin Time Test-24s; Control-16s Test-17s; Control- 16s
INR 1.54 1.06





Serum IgG (700-1600) 2230mg/dl -
Alfa fetoprotein 81.7ng/ml -
Table 1: Results of  relevant laboratory tests of  a nigerian female with autoimmune hepatitis
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DISCUSSION
Autoimmune hepatitis is a chronic inflammatory disease
of  unknown etiology that is characterized by the
presence of hypergammaglobulinemia, circulating
autoantibodies, necroinflammatory changes on hepatic
histology and a dramatic response to immuno-
suppressive therapy.2,8
The exact pathophysiologic mechanism of AIH is
unknown.5 The dominant hypothesis is that AIH is a
disease that develops in a genetically predisposed
person, who is also exposed to environmental
triggering factors.2,5,8 Subsequently, the autoimmune
attack is perpetuated possibly via molecular mimicry
and is favored by the impaired control of regulatory
T-cells.2,5,8 Several triggers have been identified which
include- drugs, viral antigens (hepatitis A, B and C)
and herbal agents.2
The clinical manifestation of AIH can range from
asymptomatic, acute hepatitis and rarely to fulminant
hepatic failure, chronic hepatitis or well-established
cirrhosis. About 25–34% may be asymptomatic.2
However, asymptomatic patients commonly become
symptomatic and thus need to be monitored.2
The immunologic tests that are indispensable for the
diagnosis of AIH are serum ANA, SMA, anti-LKM1
and IgG.2,5,8 Other immunological tests that may be
relevant include anti-actin antibody, anti-LKM3, anti-
liver cytosol 1, perinuclear antineutrophil cytoplasmic
antibodies (pANCA), and antibodies to soluble liver
antigen (SLA) or liver pancreas antigen (LP).2,5,8
The case at hand had features of chronic hepatocyte
inflammation as evidenced by the moderate elevation
of the transaminases, lower limit serum albumin and
high total protein (indicating hypergammaglobuline-
mia). Although the patient had a negative ANA, the
presence of elevated serum IgG and a positive SMA
is enough to diagnose AIH, precisely type 1, in a patient
that had no history of alcohol ingestion and any
serological marker of hepatitis B and C. The initial
dramatic response to prednisolone therapy was quite
encouraging despite the adverse effect. More reassuring
is the fact that the patient’s albumin had improved
significantly; the globulin component of the total
protein, ALT, AST and INR have normalized and the
bilirubin levels nearing normal after one year of
immunosuppressive therapy (Table 1).
The presence of conjugated hyperbilirubinemia and
the initial pruritus could have caused a diagnostic
dilemma but the disappearance of the pruritus even
after cholestyramine was stopped and the finding of
a normal biliary tree on abdominal ultrasonography
were reassuring. AIH may have cholestatic features that
can resemble primary sclerosing cholangitis or primary
biliary cirrhosis and overlap with these diseases have
been described in 10%-20% and 2%-8% of cases,
respectively.5
Features like past history of  jaundice, pedal edema,
ascites, coagulopathy, splenomegaly and coarsened liver
on ultrasound in this patient all indicate that the disease
was long standing and that she had developed liver
cirrhosis. While a histological finding of  interface
hepatitis is desirable in the diagnosis of AIH, liver
biopsy could not be performed on this patient because
of coagulopathy at the time of evaluation.
Anti-inflammatory or immunosuppressive therapy has
been the mainstay of treatment of both type 1 and
type 2 disease.2,5 When treated adequately, the 20-year
survival rate for all treated patients exceeds 80%, and
life expectancy is similar to that of age and sex-matched
normal subjects from the same geographical area.2,5
The treatment is divided into two phases: (i) induction
of remission, and (ii) remission maintenance.2,5,9
Prednisolone monotherapy and Prednisolone in
combination with Azathioprine (AZA) are alternative
induction therapies for AIH; for maintenance,
Prednisolone in combination with AZA and AZA
monotherapy are superior to Prednisolone
monotherapy.2,5,9 The combination therapy has an
advantage in the reduction of Prednisolone related side
effects. Budesonide may be used as an alternative to
Prednisolone in order to reduce steroid specific side
effects.2,5,9 We opted for the Budesonide/AZA therapy
because our patient reacted to the Prednisolone
monotherapy.
Remission of previously symptomatic patients is
defined as a complete normalization of  all
inflammatory parameters, including AST, ALT,
bilirubin, IgG, recovery from symptoms and inactive
liver histology for at least 2-3 years.9 Some patient could
relapse after cessation of  therapy. The ideal thing to
do after the first episode of relapse is to use a
Prednisolone/AZA combination therapy.2  Alternative
therapies for subsequent relapse include tacrolimus,
mycophenolate mofetil, cyclosporine, methotrexate,
cyclophosphamide, ursodeoxycholic acid, infliximab
and rituximab. Although there are some encouraging
results with each of the medications, the treatments
have not been standardized due to lack of randomized
controlled trials’ data.2,3
Liver transplantation is the ultimate rescue treatment
for all liver diseases but has only a minor role in AIH.9
Approximately 4% of liver transplantations in both
the US and Europe are due to AIH.9 The cornerstone
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of AIH management is, in fact, the avoidance of liver
transplantation by timely diagnosis and adequate
immunosuppressive therapy.9 Liver transplantation is,
however, required in patients who are refractory to or
intolerant of immunosuppressive therapy and in whom
end-stage liver disease develops.2,5,9
CONCLUSION
To the best of  our knowledge, this is the second case
report of AIH in Nigeria. There is a need to maintain
a high suspicion index for the disease and to thoroughly
evaluate all CLD cases of  apparently unknown etiology
for AIH in order to prevent progression to end-stage-
liver-disease, since AIH is highly responsive to
immunosuppressive therapy.
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